GLP-1 analogue maintains weight but bars bone loss

Being overweight might protect against osteoporosis and fractures but poses risk of cardiovascular diseases (CVD) and Type 2 diabetes. Moreover, the strategies indicated to obtain weight loss result in loss of bone mass. Menopausal women undergoing weight management are at utmost risk of osteoporosis and bone fractures. Signe Soerensen Torekov, et al in their recent study (published in the Journal of Clinical Endocrinology and Metabolism) demonstrated that liraglutide (GLP-1 analogue) with its appetite-inhibiting effects brought effective weight loss.

Additionally, it prevented bone loss instead increased bone formation marker levels in blood along with controlling blood sugar levels compared to diet-induced weight loss in women. Liraglutide is indicated in treatment of Type 2 diabetes, as well as now approved for treatment of obesity. The authors claim that liraglutide is a wonder drug as it can induce weight loss, enhance new bone formation, prevent bone loss and reduce the risk of CVD and Type 2 diabetes.

Leave a Reply